Brief: Cytokinetics Announces Launch Of Myqorzo (Aficamten) In Germany For Symptomatic Obstructive Hypertrophic Cardiomyopathy
01/06/2026 12:30
BRIEF-Cytokinetics Announces Launch Of Myqorzo (Aficamten) In Germany For Symptomatic Obstructive Hypertrophic Cardiomyopathy June 1 (Reuters) - Cytokinetics Inc CYTK.O:
CYTOKINETICS ANNOUNCES LAUNCH OF MYQORZO (AFICAMTEN) IN GERMANY FOR SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY
Source text: [ID:]
Further company coverage: CYTK.O
Recent news on Cytokinetics, Incorporated
See all newsBrief: Cytokinetics To Announce Third Quarter Results On November 4, 2026
Brief: Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Cytokinetics Announces Additional Data From Acacia-Hcm Presented At The Hfsa Annual Scientific Meeting 2026
Brief: Cytokinetics Launches Aspen-Hcm A Real-World Study Evaluating Myqorzo® (Aficamten) In Symptomatic Obstructive Hypertrophic Cardiomyopathy
U.S. STOCKS ON THE MOVE-Bleichroeder Acquisition Corp, Halliburton, BioNTech